Medicare’s 2027 drug-plan pricing benchmarks are in, and the number that matters most to retirees moved higher again. The Centers for Medicare & Medicaid Services set the national base beneficiary premium at $41.33 for 2027, up from $38.99 this year, and confirmed it will wind down a temporary premium-smoothing program that has been in place since 2025. The base premium is the anchor CMS uses when calculating what many stand-alone drug plans, and Medicare Advantage plans that include drug coverage, will ultimately charge.
The figure lands in the middle of a broader reshaping of how Medicare’s drug benefit works. Since 2025, Part D has run on a three-phase structure created by the Inflation Reduction Act: a deductible phase, an initial coverage phase, and a catastrophic phase that caps a beneficiary’s annual out-of-pocket drug spending once it is reached, with that cap indexed upward each year. The base beneficiary premium is one of several moving pieces in that redesigned benefit, and it is the piece that moved again for 2027.
How CMS Sets the Base Beneficiary Premium
The base beneficiary premium is not a bill anyone receives directly; it is a statutory benchmark built from a percentage of the drug-plan bids that Part D sponsors submit each year, adjusted for projected reinsurance costs under the redesigned Part D benefit. CMS confirmed the 2027 figure in a July 28 fact sheet, alongside a related national average monthly bid amount of $296.05, the enrollment-weighted average bid CMS uses to calculate the government subsidy paid to each plan.
A provision of the Inflation Reduction Act caps the year-over-year increase in the base premium at 6% through 2029. The move from $38.99 to $41.33 lands just under that ceiling, continuing a run of near-maximum annual increases since the cap took effect. Without that statutory cap, actuaries who track Part D bidding say the base premium likely would have risen considerably faster, given how much more of the cost of expensive drug claims plan sponsors are now absorbing directly under the redesigned benefit.
Free retirement updates: Want plain-English help keeping more of your money in retirement? The free Retirement Shield newsletter covers the benefits, deadlines, and money mistakes that cost retirees, a couple times a week. Subscribe free.
A Premium-Stabilization Program Ends After 2026
Alongside the base premium figure, CMS said it will discontinue the Part D Premium Stabilization Demonstration at the end of calendar year 2026. The voluntary program let stand-alone prescription drug plan sponsors cap their own premium increases in exchange for extra government support, a cushion CMS introduced in 2025 to offset volatility created by the IRA’s benefit redesign. CMS said its bid analysis found sponsors now have enough experience under the redesigned benefit to price plans without that support, returning Part D to what the agency called “traditional market conditions” in 2027.
The base beneficiary premium is calculated by formula regardless of the demonstration, but the plan-level premiums retirees actually pay are shaped by both pieces together. With the stabilization cushion gone, insurers have more latitude to raise premiums on individual stand-alone drug plans on top of the base premium’s own increase, which is why the two changes are landing in the same announcement.
Four Straight Years Near the Legal Maximum
The base beneficiary premium has climbed close to the Inflation Reduction Act’s 6% ceiling every year since the cap took effect: $34.70 in 2024, $36.78 in 2025, $38.99 in 2026, and now $41.33 for 2027. Each of those increases has landed within a few cents of the maximum allowed, which suggests the underlying cost pressure on drug plans — driven partly by the redesigned benefit’s higher catastrophic-coverage costs for insurers — has been strong enough to push against the cap in every cycle since it was created, rather than easing off in any single year.
That steady climb matters because the cap only limits the base premium used in the subsidy formula. It does not cap what any individual plan can charge, which is part of why the spread between the cheapest and priciest Part D plans in the same region has widened even as the base premium itself has risen predictably.
What Retirees Can Do Before Enrollment Opens
CMS will not finalize which specific plans carry which premiums until it releases the full 2027 Medicare Advantage and Part D landscape in mid-to-late September, timed to give beneficiaries several weeks to compare before Medicare’s Open Enrollment Period opens October 15 and runs through December 7. Because both the base premium increase and the end of the stabilization demonstration point toward higher costs on a number of plans, Medicare counselors typically recommend re-shopping rather than letting a current drug plan renew automatically.
A retiree already receiving Extra Help, the federal low-income subsidy, is largely shielded from this particular increase, since premiums for benchmark plans in that program are calculated on a separate track. For everyone else, the gap between the least and most expensive plan covering the same medications in the same area can run into hundreds of dollars a year, which is what makes a fall comparison worth the time even before any of these changes formally take effect. Checking a plan’s formulary alongside its premium matters just as much, since two plans priced within a few dollars of each other can cover a retiree’s specific prescriptions very differently.
This article was produced with AI assistance and reviewed by The Financial Wire editorial team.
More Financial Reading
- How many CDs can you park at 1 bank? FDIC rules you must know
- What really happens to your joint savings account when you die?
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
